EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC

Xiaoxiao Li, Yadong Guo, Shize Yang

Pharmacological Research · 2026-09 · 231 · 108367

DOI: 10.1016/j.phrs.2026.108367 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026-09. Verfasst von Xiaoxiao Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Hospital of China Medical University, China Medical University, Shenyang 110000, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies have improved outcomes in EGFR-, KRAS G12C-, and BRAF V600E-driven non-small cell lung cancer (NSCLC), but acquired resistance is molecularly and spatially heterogeneous. Driver-specific algorithms and validated biomarkers underpin post-progression care. Determining pathway activity, causal dependency, and a tractable therapeutic vulnerability requires evidence beyond detecting an acquired alteration. We propose a lesion- and time-specific pathway-dependency framework centered on the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway and the PI3K-AKT-mTOR pathway. It distinguishes three provisional biological states: MAPK-dominant resistance, shared-input MAPK-PI3K reactivation, and a candidate PI3K-enriched/MAPK-low state. A clinical management branch encompasses histologic transformation, central nervous system-limited progression, oligoprogression, and diffuse polyclonal progression and may coexist with a biological assignment. Spatially discordant mechanisms support a mixed assignment, whereas insufficient evidence remains indeterminate. Biological assignment integrates contemporaneous lesion-level findings, clonality, histology, and exploratory pathway readouts; progression pattern guides the clinical branch. The framework complements genotype-based classification and may clarify when better-supported systemic, histology-directed, or local treatment should take precedence. Evidence remains uneven: some driver-specific interventions have established clinical evidence or clinically supported activity, whereas most downstream MAPK strategies and all approaches matched to the candidate PI3K-enriched/MAPK-low state remain investigational. Limited tissue availability, spatial heterogeneity, unstandardized assays, and combination toxicity constrain implementation. Prospective studies should determine whether a locked classifier adds predictive value beyond the initiating driver and acquired genomic alterations. Until prospective validation is available, the framework is best suited to mechanistic interpretation and trial design; routine treatment continues to rely on validated biomarkers and established clinical evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Antineoplastic AgentsHumansMutationAnimalsErbB ReceptorsMolecular Targeted TherapySignal Transduction

Stichwörter der Autor:innen

Acquired resistanceMAPK signalingNon-small cell lung cancerPI3K-AKT-mTOR signalingPathway dependencyTargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ErbB ReceptorsKRAS protein, humanBRAF protein, humanAntineoplastic AgentsEGFR protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Hospital of China Medical University, China Medical University, Shenyang 110000, China.
  • Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 301 Yanchang Road, Jing'an District, Shanghai 200040, China.
  • Department of Thoracic Surgery, The First Hospital of China Medical University, China Medical University, Shenyang 110000, China. Electronic address: yszcmu@163.com.

Zitieren

APA

Li, X., Guo, Y., & Yang, S. (2026). A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. Pharmacological Research, 231, 108367. https://doi.org/10.1016/j.phrs.2026.108367

Vancouver

Li X, Guo Y, Yang S. A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. Pharmacological Research. 2026;231:108367. doi:10.1016/j.phrs.2026.108367

BibTeX
@article{Li2026,
  author = {Li, Xiaoxiao and Guo, Yadong and Yang, Shize},
  title = {A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC},
  journal = {Pharmacological Research},
  year = {2026},
  volume = {231},
  pages = {108367},
  doi = {10.1016/j.phrs.2026.108367}
}
Kostenlos starten →